UNSPSC 51112005: Imatinib

This classification denotes a tyrosine kinase inhibitor with the molecular formula C29H31N7O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BKJ8M8G5HI, chemically known as benzamide, 4-((4-methyl)-1-piperazinyl)methyl)-n-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)- but generally known as imatinib, which bears US NIH Compound Identifier 5291. European Medicines Agency schedules Imatinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25387.

UNSPSC 51112005 Imatinib is a Commodity code representing branded and generic pharmaceutical active pharmaceutical ingredients and finished-dose medications. State and local governments procure imatinib and similar pharmaceutical products through cooperative purchasing vehicles and multistate alliances that aggregate demand across participating state agencies, counties, municipalities, and public health systems. The work being solicited involves manufacturers and pharmaceutical suppliers entering into framework agreements to supply identified drugs at negotiated pricing, with products flowing through authorized pharmaceutical wholesalers to end-use state and local facilities. Issuing bodies include state departments of administration, multistate cooperative purchasing organizations, and their member jurisdictions spanning multiple states. The scope encompasses pricing negotiation, product availability certification, supply-chain security compliance, and ongoing fulfillment against standing demand from public healthcare and institutional buyers.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with participating members across Minnesota, Oregon, and other allied jurisdictions. The procurement requires manufacturers to provide comprehensive pricing for identified pharmaceutical products with specific National Drug Codes, maintain compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and establish contractual relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with chargeback systems in place. Award evaluation is weighted heavily toward price competitiveness (75 percent), with secondary weight on fixed pricing, EDI capability, administrative fee compliance, and format adherence. The contract term is two years for new vendors, with optional extensions at MMCAP's discretion and existing agreements through June 30, 2028. Vendors must carry $5 million commercial general liability insurance, $2 million network security and privacy liability, and $2 million professional liability, and face performance penalties ranging from $200 to $1,500 per violation for late reporting or missed onboarding timelines.